Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

Participants and sampling period

MN Martina Novosadova
SF Stanislav Filip
VM Veronika Molnarova
PP Peter Priester
DS Dagmar Svecova
ask Ask a question
Favorite

The clinical study comprehended the period between March 2020 to March 2022. All of the patients provided their informed consent. The inclusion criteria involved the termination of active antitumour treatment with a curative goal. A total of 250 individuals, treated on an outpatient basis, were included in the study, of which 126 were female (50.4%; x~ =71.8±11.9 years; range 21–94 years) and 124 were male (49.6%; x~ = 70.2±11.7; range 30–91 years). The Performance status scale (PS), measured according to ECOG (Eastern Cooperative Oncology Group), was estimated in 0–3 (x~=2) at the start of the clinical trial. The most common type of cancer found in these patients was colorectal cancer (n=47; 18.8%) (table 1).

Participants in the clinical study

ECOG, Eastern Cooperative Oncology Group.

Copyright and License information:  ©2023 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A